Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-2417 Alone or in Combination in Advanced Solid Tumors
NCT06682780Phase 2Recruiting
- Sponsor
- LaNova Medicines
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of LM-2417 in solid tumor (3 arms), sponsored by LaNova Medicines. Primary endpoints: Incidence of adverse events at 60 weeks, Incidence of dose-limiting toxicity at 60 weeks and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
LM-2417
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06682780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682780.